Qurient Co., Ltd. (KOSDAQ: 115180)

Market Cap	192.24B
Revenue (ttm)	8.75B
Net Income (ttm)	-21.98B
Shares Out	35.47M
EPS (ttm)	-793.68
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	52,424
Average Volume	132,408
Open	5,420.00
Previous Close	5,420.00
Day's Range	5,270.00 - 5,450.00
52-Week Range	3,200.00 - 5,860.00
Beta	0.54
RSI	64.27
Earnings Date	Mar 20, 2025

About Qurient

Qurient Co., Ltd., a biotech company, engages in the research and development of drugs to address unmet medical needs in Korea and internationally. The company’s pipeline products include Q301, a topical 5LO inhibitor, which is in Phase II clinical trial for the treatment of atopic dermatitis; and Telacebec (Q203), Cyt bc1 Inhibitor, that is in Phase II to treat Mycobacterial Infections, such as tuberculosis/non-TBM. Its pipeline products also comprise Adrixetinib (Q702), an Axl/Mer/CSF1R Inhibitor, which completed phase I for the treatment of ...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2008
• Employees: 31
• Stock Exchange: KOSDAQ
• Ticker Symbol: 115180

Financial Performance

In 2023, Qurient's revenue was 9.03 billion, an increase of 6.65% compared to the previous year's 8.47 billion. Losses were -21.12 billion, -17.05% less than in 2022.